Update on previous coverage

  After a while since our last update on these stocks, we wanted to provide an update to our readers on their recent developments and what to expect in the.

A closer look at these veterinary stocks: PETX, KIN, PARN

  Animal health (AH) is gaining more and more attention from investors as new companies go public amidst the biotech IPO frenzy. In this report, we’ll focus on three new.

CAR-T in the spotlight: Cellectis

  Two weeks ago, Cellectis (ALCLS) and Pfizer (PFE) struck an agreement to develop new chimeric antigen receptor (CAR)-T-based therapies for oncology. Pfizer will pay $80M upfront and up to.


Sunesis (SNSS) The company presented a poster of an MD Anderson-sponsored trial of its investigational drug voseroxin plus decitabine. There was intriguing data with regard to the response rates. 30.

Sunesis: little value in VALOR

  Sunesis Pharmaceuticals (NASDAQ: SNSS) is expected to report top-line data from the Phase III VALOR study in the third or fourth quarter of this year. The VALOR study is.

INSM – Quick take on Insmed

 Insmed (NASDAQ: INSM) is expected to report top-line data from a Phase II trial of Arikace in non-tuberculosis mycobacteria (NTM) infection tomorrow morning. This is a double-blind placebo-controlled study that.

CYTK – Will tirasemtiv BENEFIT ALS patients?

  As Cytokinetics confirmed in its Q4 2013 conference call, it will report top-line data from the BENEFIT-ALS study in the second quarter of this year, precisely, at the American.

GenVec: hearing a comeback

On the verge of shutting down just a few months ago, Genvec (NASDAQ: GNVC) has recently had a comeback  that might last for a few more years if its partnered.

KaloBios: a look at KB003 and KB004

(jointly with Jason Chew) KaloBios (NASDAQ: KBIO) completed its initial public offering this past January, securing $61.5 million in proceeds to fund operations and it recently raised $30M in a.

CYTK – Flash note on ATOMIC-AHF data

Today, Amgen (NASDAQ: AMGN) and Cytokinetics (NASDAQ: CYTK) reported data from the Phase IIb ATOMIC-AHF study of i.v. omecamtiv mecarbil (OM) in patients with acute heart failure. As we hypothesized.

Three European biotech companies building value through partnerships

Galapagos NV Galapagos (Brussels: GLPG; Pink Sheets: GLPYY.PK) is a Belgian biotech company whose lead product is JAK1 inhibitor GLPG0634 for rheumatoid arthritis (RA) and Crohn’s disease (CD). Jason covered.

VICL – Quick take on Vical’s Allovectin failure

(With Patrick Crutcher) Today Vical (NASDAQ: VICL) reported top-line data from a Phase III trial of Allovectin-7 (A7) in patients with advanced melanoma. As we predicted in this article, the.

MACK – Flurry of results in the second half of the year

We would like to take a closer look at the upcoming results of Merrimack Pharmaceuticals’ (MACK) lead drugs, MM-398 and MM-121. MM-398 MM-398 is a liposomal formulation of irinotecan intended.

ABBV – A look into Abbvie

with Patrick Crutcher and Jason Chew Abbvie (ABBV) presented data on its oncology candidates at ASCO meeting and updated investors at Jefferies Healthcare Conference last week. The stock, like other.

CYTK – Our take on the upcoming ATOMIC-AHF study results

Results from ATOMIC-AHF, a Phase IIb clinical trial of omecamtiv mecarbil, are quickly approaching. Cytokinetics (NASDAQ: CYTK) and partner Amgen (NASDAQ: AMGN) expect to release top-line data around mid-year, probably.

VICL – Bear take on Allovectin-7

with Patrick Crutcher Vical (NASDAQ: VICL) is approaching the release of top-line data from a Phase III clinical trial of Allovectin-7 (A7) in patients with metastatic melanoma. According to the.

DCTH – Our take on Delcath’s upcoming advisory committee

The FDA’s Oncologic Drugs Advisory Committee (ODAC)  is slated to review Melblez (previously known as Chemosat) on May 2nd. An FDA decision is expected on June 15th. Melblez is a.

THRX – Insight into Relovair’s upcoming FDA Advisory Committee

On April 17th, Theravance (NASDAQ: THRX) and partner GlaxoSmithKline (LSE: GSK; NYSE: GSK) will sit in front of the FDA’s Pulmonary-Allergy Drugs Advisory Committee that will decide on whether to.

STML – Initiating coverage on new public company Stemline Therapeutics

The IPO window was almost closed in 2008 when the financial crisis hit the markets worldwide. Companies looking to raise funds from the capital markets had to think it twice.

Data and FDA decisions for 3 biotech companies EXAS PATH IPXL

Exact Sciences Exact Sciences (NASDAQ: EXAS) is expected to release full data from the DeeP-C study for Cologuard, its colon cancer screening test. The company anticipates filing a premarket approval.

Browsing 20 / articles
    1 2